Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization
VANCOUVER, BC, May 20, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the appointment of Dr. Joel Raskin as Chief Medical Officer. A trusted and respected leader in the neuroscience community, Dr. Raskin possesses two decades of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization.
As Chief Medical Officer with MINDCURE, Dr. Raskin will play a lead role in the company’s drug research, development, and commercialization approach. He has additional expertise around several priority indications identified by MINDCURE, including migraines, depression, and anxiety. Dr. Raskin earned his Medical degree and his FRCPC Psychiatry from the University of Toronto. Dr. Raskin had a 20-year career holding various neuroscience leadership positions at pharmaceutical company Eli Lilly & Co. He currently serves on the Alzheimer’s Drug Development Foundation Scientific Review Committee and the Weston Family Foundation Brain Institute Scientific Advisory Committee.
“I am thrilled today to be joining the team at MINDCURE as Chief Medical Officer,” said Dr. Joel Raskin. “In my 35 years of pharmaceutical and psychiatric experience, I have seen firsthand the shortcomings of existing treatments and drugs. It is an exciting opportunity ahead for MINDCURE, and this industry in general, to find more effective and safer treatments for psychiatric and neurological diseases.”
“As we continue to build our world-class executive team, we are extremely pleased to welcome Dr. Raskin to MINDCURE,” said Kelsey Ramsden, President and CEO of MINDCURE. “Dr. Raskin is a recognized leader in the area of neuropsychiatry research and treatment, and he will play a key role in advancing our mission to improve mental health in our communities through scientific psychedelic research and drug development.”
About Dr. Joel Raskin
Dr. Joel Raskin was a community psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization. He earned his medical degree and FRCPC, Psychiatry at the University of Toronto. He is currently on the Alzheimer’s Drug Development Foundation Scientific Review Committee and the Weston Family Foundation Brain Institute Scientific Advisory Committee.
Dr. Raskin is a member of the Canadian Medical Association, Ontario Medical Association, and Royal College of Physicians and Surgeons. As an active member of the academic and life sciences community, Dr. Raskin, until recently, held an adjunct staff appointment with the University of Toronto Department of Psychiatry.
About Mind Cure Health (MINDCURE) Inc.
MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, performance or achievements contemplated by forward-looking statements made may be materially different from the results anticipated or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the company’s ability to conduct an effective drug research, development, and commercialization program and advance its mission to improve mental health with the addition of Dr. Raskin to the team.
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that the addition of Dr. Raskin will help Mind Cure achieve its business goals; and that Mind Cure will be able to operate its business as planned.
Although Mind Cure has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Mind Cure does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.